Premenstrual dysphoric disorder

What it is

Premenstrual dysphoric disorder (PMDD) is a DSM-5–classified depressive disorder affecting an estimated 3–8% of people with menstrual cycles, characterized by severe, cyclical psychological symptoms — extreme mood swings, depression, anxiety, and irritability — that arise in the luteal phase (typically 1–2 weeks before menstruation) and resolve within a few days of the period starting. Also called severe premenstrual syndrome in older literature, PMDD is now recognized as a distinct psychiatric and hormonal condition with its own neurobiological basis, diagnostic criteria, and treatment pathway.

PMDD causes significantly greater functional impairment than ordinary premenstrual syndrome (PMS). Where PMS involves manageable premenstrual discomfort, PMDD disrupts relationships, work, and daily functioning on a monthly, predictable basis. The cyclical pattern — symptoms locked to the luteal phase and absent or minimal in the follicular phase — is what separates PMDD from an underlying depressive or anxiety disorder that simply worsens premenstrually.

In Canada, PMDD is diagnosed and managed within primary care, psychiatry, and gynecology. Canadian patients can access prospective symptom tracking tools and first-line SSRI prescriptions through family physicians, nurse practitioners, or virtual care platforms. SOGC clinical practice guidelines address premenstrual disorders as part of menstrual health management.

Causes and mechanism

PMDD is not caused by abnormal hormone levels. People with PMDD have normal estrogen and progesterone concentrations — a fact confirmed across multiple studies. The condition instead reflects an abnormal neurological sensitivity to the normal hormonal fluctuations of the menstrual cycle. Three mechanisms are best supported by current evidence:

1. Allopregnanolone sensitivity. Allopregnanolone is a neurosteroid derived from progesterone that modulates GABA-A receptors. In most people, rising allopregnanolone during the luteal phase has a calming effect. In PMDD, the brain responds to allopregnanolone in a paradoxically destabilizing way, triggering anxiety and mood dysregulation rather than sedation.

2. Serotonin system sensitivity. PMDD is associated with altered serotonin receptor sensitivity to hormonal fluctuations. This explains why SSRIs produce symptom relief within 1–2 days in PMDD — far faster than the weeks required in depression — and why intermittent luteal-phase dosing works at all.

3. Genetic factors. A 2017 NIH study identified dysregulated expression in the ESC/E(Z) gene complex, which is involved in sex steroid signalling, in people with PMDD. This adds molecular evidence that PMDD is a disorder of cellular response to estrogen and progesterone, not a hormone imbalance per se.

Risk factors include a personal or family history of depression, anxiety, PMDD, or postpartum depression; a history of trauma or adverse childhood experiences; and high chronic stress.

Symptoms and diagnosis

Symptoms must occur in the luteal phase, improve after menstruation begins, and be absent or minimal in the follicular phase (the week after the period ends).

At least one core psychological symptom is required:

• Marked mood swings, sudden sadness, or heightened sensitivity to rejection
• Marked irritability, anger, or interpersonal conflict
• Marked depressed mood, hopelessness, or self-deprecating thoughts
• Marked anxiety or tension, feeling on edge

At least five total symptoms are required for diagnosis, drawn from the above plus: decreased interest in usual activities, difficulty concentrating, fatigue, appetite changes or food cravings, sleep disturbances, feeling overwhelmed, and physical symptoms such as breast tenderness or bloating.

Feature	PMS	PMDD
Prevalence	~20–30% of cycles	3–8% of people with cycles
Psychological severity	Mild to moderate	Severe, functionally impairing
DSM-5 classification	Not classified	Depressive disorder
Requires specific treatment	Rarely	Usually yes
Follicular-phase symptoms	Possible	Absent or minimal

Diagnosis rests on three steps:

1. Prospective symptom tracking across at least two menstrual cycles using a validated tool such as the Daily Record of Severity of Problems (DRSP). This is the gold standard — retrospective recall alone is insufficient.
2. Confirmation of DSM-5 criteria: five qualifying symptoms in the luteal phase with functional impairment and symptom-free follicular phase.
3. Exclusion of underlying depression, anxiety disorder, bipolar disorder, or thyroid dysfunction that could mimic or overlap with PMDD.

Treatment options

PMDD has several well-evidenced treatments. Choice depends on symptom severity, contraceptive needs, and patient preference.

SSRIs and SNRIs (first-line): Sertraline, fluoxetine, and escitalopram are the most evidence-supported options. A defining feature of PMDD pharmacotherapy is that SSRIs can be taken intermittently — only during the luteal phase (roughly 10–14 days before the period) — rather than continuously. Symptom relief often appears within 1–2 days, consistent with rapid GABA-A/serotonin receptor modulation rather than the gradual neuroplastic changes seen in depression treatment.

Hormonal treatments:

• Combined oral contraceptives suppress ovulation, eliminating the hormonal fluctuations that trigger PMDD. The drospirenone-containing pill (e.g., Yaz, available in Canada) has specific trial evidence for PMDD.
• GnRH analogues (leuprolide, goserelin) suppress ovarian function, inducing a temporary menopause state. Highly effective for severe PMDD; used alongside add-back hormone therapy to prevent bone loss and menopausal symptoms.

Lifestyle interventions with evidence:

• Regular aerobic exercise reduces symptom severity in controlled studies.
• Calcium supplementation at 1,000–1,200 mg/day is one of the better-evidenced nutritional interventions for PMDD.
• Cognitive behavioural therapy (CBT) is effective for managing the psychological and interpersonal impacts of PMDD, and is available through provincial mental health programs or platforms such as Maple, Felix, or Cleo.

Surgical: Bilateral oophorectomy is reserved for severe, refractory PMDD unresponsive to all other treatments. It permanently eliminates the hormonal cycle driving PMDD and is followed by hormone therapy.

When to see a clinician in Canada

See a family physician, nurse practitioner, or gynecologist if psychological symptoms — particularly mood swings, irritability, depression, or anxiety — consistently appear in the 1–2 weeks before your period and reliably resolve within a few days of it starting, and if those symptoms are interfering with relationships, work, or daily functioning. Keeping a 2-month prospective symptom diary before your appointment will help confirm the cyclical pattern and support an accurate diagnosis.

In Canada, SSRI prescriptions for PMDD are available through family medicine and are covered under most provincial drug benefit programs for eligible patients. Virtual care providers (Felix, Maple, Cleo, Phoenix, and others) can initiate assessment and prescriptions where in-person access is limited.

Limitations and open questions

Research is still emerging on several fronts. The precise molecular mechanism linking allopregnanolone sensitivity to PMDD remains incompletely characterized, and no biomarker currently exists to confirm the diagnosis — it rests entirely on prospective symptom tracking. The ESC/E(Z) gene complex findings from 2017 are promising but have not yet translated into clinical testing or targeted therapies.

Health Canada has not issued a specific PMDD treatment guideline; Canadian clinicians rely on DSM-5 criteria and international guidance from bodies such as the Endocrine Society and ACOG. Evidence on long-term outcomes of GnRH analogue use for PMDD, and on the optimal duration of SSRI therapy, remains limited. The relationship between PMDD and perimenopausal depression is recognized but not yet well enough understood to guide preventive treatment decisions. People with PMDD who are transgender or non-binary are underrepresented in clinical research, and how hormonal transition affects PMDD symptom trajectories is not well established.